BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 16519039)

  • 41. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D; Smirnova O; Christiansen JS; Kanc K; le Devehat C; Wojciechowska M; López de la Torre M; Liebl A
    Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ; Pollock RF; Plun-Favreau J; White J
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Premixed insulin aspart 30 (Biasp 30) vs. premixed human insulin 30 (BHI 30) in gestational diabetes mellitus--a pilot study.
    Balaji V; Balaji MS; Alexander C; Ashalata S; Sheela Suganthi R; Suresh S; Seshiah V
    J Assoc Physicians India; 2010 Feb; 58():99-101. PubMed ID: 20653150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections.
    Mortensen H; Kocova M; Teng LY; Keiding J; Bruckner I; Philotheou A
    Pediatr Diabetes; 2006 Feb; 7(1):4-10. PubMed ID: 16489968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ; Ligthelm R; Christiansen JS; Liebl A
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs.
    Kalra S; Plata-Que T; Kumar D; Mumtaz M; Søndergaard F; Kozlovski P; Bebakar WM
    Diabetes Res Clin Pract; 2010 Jun; 88(3):282-8. PubMed ID: 20363044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
    Shah S; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shestakova M; Wenying Y; Valensi P;
    Int J Clin Pract; 2009 Apr; 63(4):574-82. PubMed ID: 19210701
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A; Ayad F; Dahaoui A; Salah-Mansour A; Berrouiguet AY
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes.
    McNally PG; Dean JD; Morris AD; Wilkinson PD; Compion G; Heller SR
    Diabetes Care; 2007 May; 30(5):1044-8. PubMed ID: 17277042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.